Theraclion announced that in its extraordinary shareholders' general meeting was held on May 12, 2016 approved resignation of Laurent Levy as director, appointment of Samuel Levy as director, and appointment of Wolfram Eichner as director. In 2009, Samuel Levy co-founded Allurion Technologies. He is currently Chairman of Allurion Technologies. Wolfram Eichner has 25 years of experience in the pharmaceuticals industry, working for companies including Beiersdorf AG and Fresenius Kabi. He was a member of BPI's board of directors between 2001 and 2005. He also has financial expertise, which he developed at ComInvest Asset Management Gmbh, where he worked as a healthcare analyst between 2006 and 2010. Since 2011, he has been a manager and analyst at Apus Capital, a German investment fund.